IVIEW Therapeutics announced today that its innovative gene therapy candidate GVB-2001 has successfully completed treatment of the first patient with primary open-angle glaucoma (POAG), marking a key clinical milestone and opening a new chapter for glaucoma management unconstrained by patient-specific genetic backgrounds.
The procedure was performed under the direction of Professor Peirong Lu, Chairman of Ophthalmology at the First Affiliated Hospital of Soochow University. The patient has completed a two-week safety follow-up with no drug-related adverse events observed and a downward trend in intraocular pressure (IOP), representing an important advance in translating this first-in-class therapy into human use.
The clinical study has been approved by the Ethics Committee of the First Affiliated Hospital of Soochow University and registered on ClinicalTrials.gov (NCT06921317). The trial is being conducted in full accordance with international GCP standards to ensure scientific rigor and patient protection.
GVB-2001 is a first-in-class gene therapy candidate developed by IVIEW Therapeutics for primary open-angle glaucoma. It is also the world’s first glaucoma gene therapy designed for all POAG patients without stratifying by genetic subtype. The product utilizes an optimized self-complementary AAV vector delivered by a single intracameral injection directly to the trabecular meshwork, the anatomical core of aqueous outflow obstruction in glaucoma. By modulating cellular function and enhancing aqueous humor outflow, GVB-2001 enables rapid, durable IOP control, intervenes at the level of disease mechanism, and aims to reduce irreversible optic nerve damage at its source.
Compared with standard therapy, GVB-2001 delivers three key innovations:
Genetic universality — The therapy requires no genetic background screening, potentially benefiting the estimated 60 million POAG patients worldwide, overcoming the narrow applicability of current genetic-targeted approaches.
One-time, long-acting administration — Preclinical studies demonstrated sustained IOP-lowering efficacy, eliminating lifetime dependence on topical drops, which suffer from poor adherence and ocular-surface toxicity.
Precise, localized delivery — Targeted administration to diseased tissue minimizes surgical trauma and reduces risks of fibrosis, tissue scarring, and other complications, offering a new option for refractory patients.
The first patient treated presented with no light perception in the study eye and had undergone multiple prior glaucoma surgeries with persistently uncontrolled IOP, representing a clinically recognized refractory case. After stringent screening and ethical review, the patient received a single intracameral dose of GVB-2001. At the two-week follow-up, the study eye demonstrated excellent tolerability, with no drug-related adverse events, no clinically significant inflammation, and no acute IOP spikes—primary safety endpoints of interest. The observed decline in IOP suggests the potential to reduce reliance on multiple anti-glaucoma medications, supporting continued long-term follow-up to evaluate sustained safety, IOP stability, and therapeutic durability.
Professor Peirong Lu, Principal Investigator and Chairman of Ophthalmology at the First Affiliated Hospital of Soochow University, stated:
“Primary open-angle glaucoma is an irreversible blinding disease, yet today’s treatments largely provide symptomatic control rather than halting underlying progression. Adherence to lifelong medications is poor, and surgical risk remains substantial. Clinical needs are far from met.
The successful first-patient administration of GVB-2001 preliminarily validates its safety and IOP-lowering potential even in refractory cases, and establishes a new gene-therapy paradigm that does not require genetic screening. We will execute the study rigorously, fully assess its clinical value, and strive to deliver safer and more effective therapeutic options for patients.”
Dr. Bo Liang, Co-Founder, Chairman, and Chief Executive Officer of IVIEW Therapeutics, commented:
“GVB-2001 is a cornerstone asset in our ocular gene-therapy pipeline. Its novel vector design and trabecular-meshwork-targeted delivery enable a ‘one-dose, long-benefit’ treatment profile. As the world’s first gene therapy designed for all POAG patients, it has the potential to redefine glaucoma care. We will fully support clinical development and accelerate translation of this breakthrough therapy to benefit patients worldwide.”
About IVIEW Therapeutics Inc.
IVIEW Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative ophthalmic therapies. We invest in novel mechanisms of action and differentiated drug delivery platforms to create therapies with superior clinical profiles that address significant unmet medical needs. Our pipeline includes small molecules and gene therapies for dry eye, myopia, conjunctivitis, glaucoma, and presbyopia. The U.S. headquarters is in Cranbury, New Jersey, with 11,045 square feet of combined laboratory and office space in the Princeton area.
For additional information, please visit www.iviewtherapeutics.com
Media Contact:
Wei Wang, PhD; VP of Translational Research and Head of Operations
Email: weiwang@iviewinc.com